AAPG

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +0.29
Percentage change 1.56	%

Index	-	P/E	-	EPS (ttm)	-0.70	Insider Own	-	Shs Outstand	52.23M	Perf Week	-5.07%
Market Cap	1.64B	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	5.99%
Income	-49.71M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Sales	125.11M	P/S	13.10	EPS this Y	-	Inst Trans	31.61%	Short Ratio	0.84	Perf Half Y	-
Book/sh	1.35	P/B	14.03	EPS next Y	-	ROA	-11.99%	Short Interest	0.14M	Perf Year	-
Cash/sh	1.75	P/C	10.82	EPS next 5Y	-	ROE	-53.26%	52W Range	16.50 - 21.40	Perf YTD	8.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.77%	ROI	-20.79%	52W High	-11.59%	Beta	-
Dividend TTM	-	Quick Ratio	1.83	Sales past 5Y	186.51%	Gross Margin	87.26%	52W Low	14.67%	ATR (14)	0.85
Dividend Ex-Date	-	Current Ratio	1.84	EPS Y/Y TTM	63.29%	Oper. Margin	-37.93%	RSI (14)	50.75	Volatility	3.50% 4.07%
Employees	583	Debt/Eq	2.22	Sales Y/Y TTM	239.00%	Profit Margin	-39.73%	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	1.27	EPS Q/Q	-	Payout	-	Rel Volume	0.12	Prev Close	18.63
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Mar 27 BMO	Avg Volume	168.12K	Price	18.92
SMA20	-2.21%	SMA50	0.91%	SMA200	0.91%	Trades		Volume	20,797	Change	1.56%

Mar-12-25 08:46AM	Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025 (GlobeNewswire)
Mar-06-25 05:18PM	Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment (Exec Edge)
Mar-05-25 06:00PM	Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (GlobeNewswire)
Feb-07-25 08:24AM	Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares (GlobeNewswire)
Jan-28-25 04:01PM	Ascentage Pharma Announces Closing of U.S. Initial Public Offering (GlobeNewswire)

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Ascentage Pharma Group International ADR

Upgrade your FINVIZ experience